Dynacure, a clinical stage drug development company focused on improving the lives of patients with rare and orphan disorders, today announced that The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Clinical Trial Application (CTA) for DYN101, an investigational antisense medicine designed to modulate the expression of dynamin 2 (DNM2) for the treatment of Centronuclear Myopathies (CNM)
AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treatments for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF)
The Janssen Pharmaceutical Companies of Johnson & Johnson have announced that a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) has been submitted by ViiV Healthcare for the investigational once-monthly, injectable, two-drug regimen of Janssen's rilpivirine and ViiV's cabotegravir for the treatment of HIV in adults whose viral load is suppressed and who are not resistant to cabotegravir or rilpivirine
AVROBIO, Inc. (the “Company”), a Phase 2 clinical-stage gene therapy company, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for AVR-RD-01, its gene therapy candidate for the treatment of Fabry disease
Physics and Chemistry scholars from Hong Kong Baptist University (HKBU) have invented a new method which could speed up the drug discovery process and lead to the production of higher quality medicinal drugs which are purer and have no side effects
Prescient Medicine Holdings Inc. announced today it has acquired AutoGenomics Inc., a privately-held U.S. molecular diagnostics company, which has developed and commercialized the INFINITI® platform – a 510(k) exempt, automated, microarray-based multiplexing diagnostic system with applications in personalized medicine, pain management, cardiovascular health, mental health, women's health, oncology, infectious diseases and genetic disorders
Allegro Ophthalmics, LLC, a privately held biopharmaceutical company focused on the development of novel anti-integrin therapies for the treatment of ocular diseases, recently announced the expansion of the company’s anti-integrin portfolio with the new front-of-the-eye-drug candidate ALG-1007
Exelixis, Inc. recently announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercialization of cabozantinib in Japan, has applied to the Japanese Ministry of Health, Labor and Welfare (MHLW) for approval to manufacture and sell CABOMETYX (cabozantinib) as a treatment for unresectable and metastatic renal cell carcinoma (RCC) in the country
“Every day is a little bit different because there’s either a new face, or someone doing something new, or there’s a new client,” says Jamie Hodgson, Director of Strategic Partnerships at Antibody Analytics when asked about a typical day at the office
When you eat something super tasty, ever wonder why you really don’t want to stop even though you know you’ve eaten enough? Scientists at the UNC School of Medicine may have found the reason. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190424006034/en/ Neurons in the mouse central amygdala involved in hunger. (Photo: Business Wire) In lab experiments, Thomas Kash, PhD, the John R. Andrews Distinguished Professor in the Department of Pharmacology,
|
|
|
|
|
|
|
|
|